Results of a small, observational study conducted at the University at Buffalo suggest that liraglutide, an injectable medication used to treat type 2 diabetes, also helps type 1 diabetics on insulin achieve optimal control of their blood glucose levels.
If the findings are confirmed in a larger, prospective, randomized study now being planned by the UB researchers, they could mean the first significant, new treatment for type 1 diabetes since insulin was discovered and made available in the 1920s.
The research has been published online ahead of print at http://www.eje-online.org/content/early/2011/06/06/EJE-11-0330.abstract ('doi: 10.1530/EJE-11-0330') in the European Journal of Endocrinology. It also was recently presented at the annual meeting of the Endocrine Society in Boston, where it received recognition as one of the most outstanding abstracts presented and the best in the field of diabetes.
"Since the development of injectable insulin, there has been nothing definitive in terms of a significant advance in type 1 diabetes treatments," says Paresh Dandona, MD, PhD, UB distinguished professor of medicine in the School of Medicine and Biomedical Sciences and senior author on the study. "That is the tragedy of the type 1 diabetic.
"This study shows that liraglutide can provide even well-controlled type 1 diabetics with additional benefits that help them achieve even better blood glucose levels," says Dandona.
The patients on liraglutide, which is marketed as Victoza, also saw a reduction in appetite and food intake and the paper reports that body weight significantly fell in patients who took the drug for 24 weeks.
The unfunded study was a retrospective analysis of data. It was conducted at Kaleida Health's Diabetes-Endocrinology Center of Western New York, which Dandona directs.
At the start of the study, all 14 patients had hemoglobin A1C levels of under 7, which is considered optimal. They were characterized in the paper as "well-controlledÂ…meticulous and disciplined" in terms of their ability to control their blood glucose levels with insulin.
Nevertheless, Dandona notes, even well-controlled type 1 diabetics still experience "glycemic excursions," fairly wide swings in their blood glucose numbers ranging from the hyperglycemic, from 150 milligrams per deciliter to 250 mg/dl or higher to the hypoglycemic, under 70 mg/dl.
"The addition of liraglutide to insulin therapy in these well-controlled type 1 diabetics resulted in a significant and rapid reduction in glycemic excursions and, as a consequence, a rapid reduction in the amount of insulin they needed to take," Dandona explains.
Several figures in this presentation by Dandona clearly demonstrate this effect.
These improvements occurred rapidly, within 1-2 days of beginning treatment with liraglutide and they reversed just as rapidly when treatment was discontinued, signifying that it was the drug that was responsible for these beneficial effects.
The mechanism behind these improvements is not well-understood but Dandona and his co-authors suggest that liraglutide may be suppressing the post-meal increase in glucagon, the hormone that raises glucose levels, in type 1 diabetics.
Dandona and his colleagues are now planning a much larger, multicenter study of liraglutide in type 1 diabetics.
"We will be investigating in detail the hypothesis that it is liraglutide's ability to suppress glucagon that significantly reduces the wide swings in blood glucose levels that type 1 diabetics -- even those with very good glucose control -- live with everyday," says Dandona.
The retrospective study involved 14 adult type 1 diabetics who took liraglutide for periods ranging from one week to 24 weeks.
Co-authors with Dandona are: Ajay Varanesi, endocrinology fellow; Natalie Bellini, honorary research fellow; Deepti Rawal, MD, UB medical resident; Mehul Vora, clinical assistant instructor; Sandeep Dhindsa, assistant professor of medicine; Antoine Makdissi, assistant professor of medicine; and Ajay Chaudhuri, MD, associate professor of medicine.
The University at Buffalo is a premier research-intensive public university, a flagship institution in the State University of New York system and its largest and most comprehensive campus. UB's more than 28,000 students pursue their academic interests through more than 300 undergraduate, graduate and professional degree programs. Founded in 1846, the University at Buffalo is a member of the Association of American Universities.
Further reports about: > Biomedical Science > Diabetes-Endocrinology Center > Drug Delivery > Glycemic > Insulin > blood glucose > blood glucose level > diabetes treatment > diabetics > glucose control > glucose levels > glycemic excursions > hyperglycemic > significantly > type 1 diabetes > type 2 diabetes
The Great Unknown: Risk-Taking Behavior in Adolescents
19.01.2017 | Max-Planck-Institut für Bildungsforschung
A sudden drop in outdoor temperature increases the risk of respiratory infections
11.01.2017 | University of Gothenburg
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
20.01.2017 | Awards Funding
20.01.2017 | Materials Sciences
20.01.2017 | Life Sciences